Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
RANDOX LABORATORIES
FOCUS DIAGNOSTICS, INC.

New Adiponectin Test Kit Gains CE Approval

By Labmedica International staff writers
Posted on 08 Jul 2014
An automated immunoturbidimetric assay for adiponectin enables more convenient and time efficient measurement than traditional ELISA-based tests, facilitating risk assessment for developing type-2 diabetes and cardiovascular disease.

Randox Laboratories (Antrim, Northern Ireland, UK) has gained CE Approval for its recently launched biochemistry assay for adiponectin. Testing adiponectin allows assessment of the risk of developing Type 2 diabetes and Cardiovascular Disease (CVD). In using latex-enhanced immunoturbidimetric technology, Randox has brought a superior option for adiponectin assessment to clinical diagnostics.

Adiponectin, a protein hormone produced and secreted exclusively by adipocytes, regulates metabolism of lipids and glucose, and influences response to insulin. Higher levels of adiponectin are correlated with increased insulin sensitivity, leading to decreased diabetes risk. Adiponectin also has anti-inflammatory effects on the cells lining the walls of blood vessels. Therefore, low levels of adiponectin can be indicative of insulin resistance leading to type 2 diabetes and of cardiovascular disease (CVD). Low adiponectin levels have also been correlated with increased likelihood of a woman developing gestational diabetes in pregnancy.

The Randox Adiponectin Assay can also be used on a variety of clinical chemistry analyzer systems. It has an extensive measurement range (4–28 µg/mL), facilitating the accurate detection of reduced adiponectin levels. Two levels of adiponectin controls as well as an adiponectin calibrator are also offered, delivering a complete testing package.

Speaking after the CE approval announcement, Randox Managing Director Dr. Peter FitzGerald said, “Increasing sedentary and deskbound lifestyles are driving chronic conditions such as diabetes and cardiovascular disease: 382 million people currently live with diabetes across the world and according to the International Diabetes Federation, this figure is predicted to rise by 55% by 2015. Adiponectin assesses an individual’s risk of developing diabetes, and allows resources and treatment to be focused on those patients most at risk. This highly targeted strategy should help to decrease the number of people becoming diabetic, while using resources most effectively.”

Related Links:

Randox Laboratories 



KARL HECHT GMBH & CO KG
CELLAVISION AB
MEDLAB Asia
PERIPHERAL VISIONS INC

Channels

Hematology

view channel
Image: Plastic bag containing 0.5 to 0.7 liters of packed red blood cells in citrate, phosphate, dextrose, and adenine (CPDA) solution (Photo courtesy of Fresenius HemoCare).

Transfusion Protocols Compared After Cardiac Surgery

Unnecessary blood transfusions may increase healthcare costs both directly, because blood is an increasingly scarce and expensive resource, and indirectly due to the complications associated with transfusion.... Read more

Industry News

view channel

Latin America’s IVD Sector Exceeds USD 2 Billion, Brazil leads

The Latin American in vitro diagnostics (IVD) sector was estimated at USD 2.4 billion in 2014. Population growth, government insurance, newly insured patients, and updated healthcare facilities have driven growth in the region and will continue to propel demand, according to Kalorama Information (New York, NY, USA).... Read more
 

Events

06 Apr 2015 - 08 Apr 2015
07 Apr 2015 - 09 Apr 2015
13 Apr 2015 - 16 Apr 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.